Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart.

Fu X, Khalil H, Kanisicak O, Boyer JG, Vagnozzi RJ, Maliken BD, Sargent MA, Prasad V, Valiente-Alandi I, Blaxall BC, Molkentin JD. · 2018

Read Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart. by Fu X, Khalil H, Kanisicak O, Boyer JG, Vagnozzi RJ, Maliken BD, Sargent MA, Prasad V, Valiente-Alandi I, Blaxall BC, Molkentin JD. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5957472.txt.

Introduction

Fu and co-authors trace how fibroblasts pass through set states to build scar in the infarcted mouse heart. Their study appeared in The Journal of Clinical Investigation. After a heart attack, dead muscle cells are replaced by matrix. Proliferating fibroblasts secrete that matrix. The team used three lineage-tracing mouse models. Stage-specific gene profiling sorted the cells over time.

Fibroblasts peaked in growth two to four days after injury, they report. Their numbers rose 3.5-fold and stayed high long term. By days three to seven they became matrix-secreting myofibroblasts. Later they settled into a new stable state, the matrifibrocyte. The same cell type appeared in human heart scars.

Catalog record

CREATORFu X, Khalil H, Kanisicak O, Boyer JG, Vagnozzi RJ, Maliken BD, Sargent MA, Prasad V, Valiente-Alandi I, Blaxall BC, Molkentin JD.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE72 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5957472

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart By Xing Fu, Hadi Khalil, Onur Kanisicak, Justin G Boyer, Ronald J Vagnozzi, Bryan D Maliken, Michelle A Sargent, Vikram Prasad, Iñigo Valiente-Alandi, Burns C Blaxall, Jeffery D Molkentin Published in: The Journal of Clinical Investigation DOI: 10.1172/JCI98215 ABSTRACT Abstract Fibroblasts are a dynamic cell type that achieve selective differentiated states to mediate acute wound healing and long-term tissue remodeling with scarring. With myocardial infarction injury, cardiomyocytes are replaced by secreted extracellular matrix proteins produced by proliferating and differentiating fibroblasts. Here, we employed 3 different mouse lineage-tracing models and stage-specific gene profiling to phenotypically analyze and classify resident cardiac fibroblast dynamics during myocardial infarction injury and stable scar formation. Fibroblasts were activated and highly proliferative, reaching a maximum rate within 2 to 4 days after infarction injury, at which point they expanded 3.5-fold and were maintained long term. By 3 to 7 days, these cells differentiated into myofibroblasts that secreted abundant extracellular matrix proteins and expressed smooth muscle α-actin to structurally support the necrotic area. By 7 to 10 days, myofibroblasts lost proliferative ability and smooth muscle α-actin expression as the collagen-containing extracellular matrix and scar fully matured. However, these same lineage-traced initial fibroblasts persisted within the scar, achieving a new molecular and stable differentiated state referred to as a matrifibrocyte, which was also observed in the scars of human hearts. These cells express common and unique extracellular matrix and tendon genes that are more specialized to support the mature scar. Keywords: Cardiology Keywords: Cardiovascular disease INTRODUCTION Fibroblasts are a unique cell type of mesenchymal origin that are present in essentially all tissues and organs, where they regulate extracellular matrix (ECM) production and acute wound healing (1–3). In addition to regulating local fibrosis and ECM production, fibroblasts also secrete growth factors to support tissue regeneration in coordination with inflammatory cells (4–6). In response to injury, tissue stretching, and cytokines such as TGF-β, fibroblasts become activated and then differentiate into a cell type referred to as a myofibroblast. Once induced, myofibroblasts produce and secrete greater levels of ECM proteins, including multiple types of collagen, and they express contractile genes, such as smooth muscle α-actin (αSMA), that underlie their ability to contract and close a wounded area (7, 8). In addition to forming myofibroblasts, unactivated tissue-resident fibroblasts have been reported to differentiate into endothelial cells and perhaps even tissue parenchymal cells at a low frequency (9–11), suggesting that these cells have some degree of multilineage competency. In most tissues or organs, injury-induced fibrosis is a transient process that typically regresses once the healing response is finalized (4, 12–14). However, the heart is perhaps one of the more unique organs with respect to the fibrotic response and wound healing, as this tissue is not inherently regenerative and a stable scar must quickly form to prevent ventricular wall rupture. Heart disease remains the number one cause of mortality in the Western world, with atherosclerosis and subsequent myocardial infarction (MI) injury representing the most lethal subset of disease (15, 16). Acute MI causes rapid necrotic and apoptotic loss of cardiomyocytes within the ischemic region, and thereafter, the activity of fibroblasts becomes critical in buttressing the ventricular wall as the fibrotic scar forms over several days (17–20). Previous work has shown that αSMA+ myofibroblasts are present within the infarct area after acute MI injury (21). While multiple cell types have been suggested as generating myofibroblasts in the diseased heart, more recent genetic lineage–tracing analysis has shown that tissue-resident fibroblasts of developmental epicardial origin, which make up approximately 12% of all the cells in the adult rodent heart, are the overwhelming source for myofibroblast generation (22–25). Despite the critical role that fibroblasts play in the diseased heart, the field has lacked an in-depth understanding of this cell type and its dynamics with MI injury. However, with the recent advent of multiple genetic lineage–tracing mouse models, it is now possible to dissect these cells and determine their phenotypic and functional characteristics during MI injury. Here, we used fibroblast stage-specific lineage tracing along with mechanistic analysis of MI-injured mice and mRNA expression profiling to annotate the stable differentiated states and dynamics of fibroblasts in the heart, which defines a fibroblast state referred to as the matrifibrocyte that resides within the mature scar. RESULTS Cardiac fibroblast proliferation following MI. To examine the proliferation dynamics of cardiac fibroblasts in response to MI, we employed a lineage tracking system with Tcf21MCM/+;R26EGFP mice that expresses the MerCreMer tamoxifen-regulated protein under the control of the transcription factor 21 (Tcf21) gene locus (26) in conjunction with a loxP site–dependent EGFP reporter that resides within the ubiquitous Rosa26 gene locus (Figure 1A and Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI98215DS1). We previously showed that this lineage-tracing reporter system identifies the vast majority of tissue-resident cardiac fibroblasts in the uninjured and injured adult mouse heart (23). Here, 4-week-old Tcf21MCM/+;R26EGFP mice were put on tamoxifen diet for 4 weeks to specifically label all resident fibroblasts; thereafter, the mice received an MI surgical procedure at 9 weeks of age (Figure 1B and Supplemental Figure 1B). To quantify proliferating cells, a single dose of 5-ethynyl-2′-deoxyuridine (EdU) was given to mice for 4 hours at multiple selected time points after MI injury, followed by heart removal and IHC examination of EdU and Ki67 staining (Figure 1B and Supplemental Figure 1B). The data show that 1 to 2 days after MI injury, Tcf21 lineage–traced fibroblasts did not proliferate in the infarct region of the heart, although by day 3, there was a robust induction of proliferation (Figure 1, C and E, and Supplemental Figure 1C). The border zone region showed proliferation of Tcf21 lineage–traced fibroblasts 1 day earlier, likely because most of the fibroblasts died within the infarct region and 1 additional day was needed for these cells to move into the infarct from the border zone (Figure 1, D and E). In the infarct region, fibroblasts continued to proliferate through day 7, although proliferation in the border zone was extinguished after day 3 (Figure 1, C–E, and Supplemental Figure 1C). These data indicate that resident cardiac fibroblasts proliferate robustly within 2 days of MI injury, reaching a peak by 2 to 4 days, with reduced but detectable proliferation thereafter through day 7 within the infarct. [Figure: Proliferation of Tcf21 lineage–traced fibroblasts after MI.(A) Schematic of the Tcf21 genetic locus with a tamoxifen-regulated MerCreMer cDNA cassette inserted into exon 1 (E1).The MerCreMer-containing Tcf21 locus was introduced into R26EGFP mice containing a loxP site–flanked stop cassette upstream of EGFP to allow for Cre-dependent lineage tracing. (B) Experimental scheme whereby Tcf21MCM/+;R26EGFP mice were given tamoxifen for 4 weeks and rested for 1 week before MI surgery. Mice were treated with a single EdU injection at the indicated time points after MI, and hearts were harvested 4 hours after each EdU injection for IHC analysis. (C–E) Quantification of EdU+ (white) and Ki67+ (red) Tcf21 lineage–traced (EGFP+) fibroblasts (green) in infarct region (C) and border zone (D) after a single EdU injection at the indicated time points after MI by IHC and representative IHC images. The white bar in C represents a 0 time point. (E) Nuclei are shown with

Read the complete text